Galecto signs massive deal with BMS
Sweden-based biotech Galecto with Dane Hans Schambye at the helm, has struck a potential multi-million-dollar deal with Bristol-Myers Squibb, which gives the US giant an option to acquire its biotech partner.
BY BENJAMIN WERNER CHRISTENSEN
USD 444 million – that is the potential value of the deal the small biotech company Galecto has struck with US giant Bristol-Myers Squibb , the Danish-led, Sweden-based biotech writes in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Something’s stirring…
For abonnenter
Sunstone to triple investments in 2012
For abonnenter
Newly formed biotech company with fresh capital
For abonnenter
